UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 14A

          CONSENT STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
                    AND EXCHANGE ACT OF 1934 (AMENDMENT NO. )

Filed by the Registrant [  ]
Filed by a Party other than the Registrant [X]

Check the appropriate box:
[  ]      Preliminary Proxy Statement
[  ]      Confidential, for Use of the Commission Only (as permitted by
          Rule 14a-6(e)(2))
[  ]      Definitive Proxy Statement
[X ]      Definitive Additional Materials
[  ]      Soliciting Material Pursuant to sec. 240.14a-12
                                 NEOPHARM, INC.
                (Name of Registrant as Specified in its Charter)
                              JOHN N. KAPOOR, PH.D.
   (Name of Person(s) Filing Consent Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X ]           No fee required.
[  ]           Fee computed on table below per Exchange Act Rules 14a-6(i)(l)
               and 0-11

(1)            Title of each class of securities to which transaction applies:

(2)            Aggregate number of securities to which transaction applies:

(3)            Per unit price or other underlying value of transaction computed
               pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
               the filing fee is calculated and state how it was determined):

(4)            Proposed maximum aggregate value of transaction:

(5)            Total fee paid:

[  ]           Fee paid previously with preliminary materials.

[  ]           Check box if any part of the fee is offset as provided by
               Exchange Act Rule 0-11(a)(2) and identify the filing for which
               the offsetting fee was paid previously. Identify the previous
               filing by registration statement number, or the Form or Schedule
               and the date of its filing.

(1)            Amount Previously Paid:

(2)            Form, Schedule or Registration Statement No.:

(3)            Filing Party:

(4)            Date Filed:





       SHAREHOLDER AND DIRECTOR KAPOOR FILES DEFINITIVE CONSENT STATEMENT

         LAKE FOREST, IL - September 27, 2004. John N. Kapoor, Ph.D., a director
of NeoPharm, Inc. (Nasdaq: NEOL) and, together with his wife, the beneficial
holder of approximately 21.7% of its outstanding common stock, today announced
that he has filed with the Securities and Exchange Commission a definitive
consent statement for the purpose of removing four of NeoPharm's six current
directors, replacing them with three new directors and reducing the size of the
board to five.

Dr Kapoor's goals are to improve NeoPharm's long-term viability and stock price
by working toward the following objectives:

         focusing NeoPharm's efforts on commercializing its IL 13-PE38QQR drug
         product candidate,

         restructuring substantially NeoPharm's operations with a goal to reduce
         its cash burn rate to approximately $30 million annually, in order that
         the Company's cash resources will be preserved for the
         commercialization of IL13-PE38QQR and the development of its liposomal
         products,

         streamlining NeoPharm's clinical trials to improve their efficiency
         with a goal to allow continued development of the Company's liposomal
         products and IL 13-PE38QQR within a cash burn rate goal of
         approximately $30 million annually, and

         eliminating the need to rely on the public equity markets and/or
         private placements in the near future to fund current clinical trials.

Dr. Kapoor intends to first mail the definitive consent statement, and the
related WHITE consent card, to NeoPharm stockholders on or about September 28,
2004, which is also the record date for the consent solicitation.

         Investors and stockholders are urged to read the definitive consent
         statement filed by Dr. Kapoor relating to the solicitation of consents
         of NeoPharm stockholders because it contains important information. Dr.
         Kapoor filed the definitive consent statement on September 27, 2004
         with the SEC and intends to mail the definitive consent statement to
         NeoPharm's stockholders on or about September 28, 2004. Investors and
         stockholders may obtain a free copy of the definitive consent statement
         and other documents filed by Dr. Kapoor with the SEC at the SEC's
         website at www.sec.gov. In addition, documents filed with the SEC by
         Dr. Kapoor may be obtained free of charge from Innisfree M&A
         Incorporated at (888) 750-5834 or by request to EJ Financial
         Enterprises, Inc., 225 East Deerpath Road, Suite 250, Lake Forest, IL
         60045, Attention: Michael Babich.

         CERTAIN INFORMATION CONCERNING PARTICIPANTS

         Dr. Kapoor, certain of the employees of EJ Financial and Dr. Kapoor's
         nominees for the directorships of NeoPharm, among others, may be deemed
         to be participants in the solicitation of NeoPharm's stockholders. The
         stockholders of NeoPharm may obtain information regarding the names,
         affiliations and interests of individuals who may be participants in
         the solicitation of NeoPharm's stockholders in the definitive consent
         statement filed by Dr. Kapoor with the SEC on Schedule 14A on September
         27, 2004.








Source:  EJ Financial Enterprises, Inc.
         Michael L. Babich (847) 296-8665 ext. 120